Overview
Quick answer
Survodutide is not approved anywhere, including Australia, and it is not on the Australian Register of Therapeutic Goods.
Unlike much of what gets discussed alongside it, its phase 3 obesity results are genuinely published. The weight-loss figure you have probably seen is not the one in the paper, and the gap between those two numbers is the most useful thing on this page.
Overview
Key takeaways
Survodutide is one molecule that switches on two receptors: the glucagon receptor and the GLP-1 receptor.
Published mechanism work describes it lowering weight by raising energy expenditure through the liver and reducing energy intake through the brain.
MASH is metabolic dysfunction-associated steatohepatitis, the form of fatty liver disease where the liver is inflamed as well as fatty.
Survodutide is not approved by any medicines regulator, including in Australia.
A search of the Australian Register of Therapeutic Goods returns no matching results for survodutide.
It acts on the glucagon receptor alongside GLP-1, a different combination from the GIP-based medicines.
Two phase 3 trials were published in peer-reviewed journals on 7 June 2026.
The figure most coverage quotes assumes everyone stayed on treatment, and the published trial figure is lower.
Roughly a quarter of participants stopped because of adverse effects, against about one in twenty on placebo.
Liver improvement in the phase 2 trial was confirmed by biopsy, and the phase 3 liver trial used MRI instead.
The widely quoted liver figure of 84.2 per cent is also an efficacy estimand, and the same paper reports 68.5 per cent on the other analysis.
Breakthrough Therapy and PRIME are development designations, not approvals.
Basics
What Survodutide is and how it works
Survodutide is an investigational medicine developed by Boehringer Ingelheim, co-invented with Zealand Pharma. It acts on two receptors: glucagon and GLP-1.
That combination is what makes it different from the medicines people usually compare it to. Semaglutide acts on GLP-1 alone. Tirzepatide adds GIP, a different receptor again. Survodutide is the only one of the three that engages the glucagon receptor.
Saying it "acts on the glucagon receptor" explains nothing on its own, and most coverage stops there. What that second receptor actually does is the reason this molecule was taken into liver disease at all.
What "dual agonist" means
An agonist is a molecule that switches a receptor on, standing in for the hormone that normally does it. A dual agonist switches on two. Survodutide is one molecule that fits both the glucagon receptor and the GLP-1 receptor. It is not two medicines given together.
The GLP-1 receptor, acting in the brain
GLP-1 is glucagon-like peptide-1, a hormone the gut releases in response to food. Australian general practice guidance describes its effects as stimulating insulin secretion, reducing glucagon secretion, slowing gastric emptying and promoting satiety. Published mechanism work describes survodutide activating GLP-1 receptors in the brain regions that signal fullness, which reduces how much a person eats.
The glucagon receptor, acting on the liver
This is the half that is unfamiliar. Published mechanism work describes survodutide’s effect on body weight as the sum of two things: energy intake reduced through the GLP-1 receptor in the brain, and energy expenditure increased through activation of the glucagon receptor in the liver. Eating less is one lever. Burning more is the other.
Why that points at the liver
Because half the mechanism operates in the liver, survodutide was taken into liver disease as well as obesity, and the liver trials are the more detailed part of its evidence base. It is also why its liver endpoints were measured by biopsy and imaging rather than by the blood markers people expect.
This is why survodutide is studied heavily in liver disease as well as obesity, and why its liver results are the more interesting half of its evidence base.
Plain language
What MASH and MASLD mean
These terms run through every report of survodutide’s liver results, and they are rarely explained. They are worth two minutes, because the difference between them is the difference between a fatty liver and an inflamed one.
MASLD
MASLD is metabolic dysfunction-associated steatotic liver disease. Steatotic means fatty, so the name describes fat accumulating in the liver alongside metabolic risk factors such as obesity or type 2 diabetes. It is the broader of the two conditions, and it is what the phase 3 liver trial was named after.
MASH
MASH is metabolic dysfunction-associated steatohepatitis. Hepatitis means inflammation of the liver, so MASH is the form where the liver is not only fatty but inflamed and its cells are being damaged. It is the more serious end of the same disease, and the phase 2 trial required participants to have it confirmed by biopsy.
Fibrosis and steatosis
Steatosis is the fat itself. Fibrosis is scar tissue laid down in response to sustained liver injury, and it is graded in stages: the phase 2 trial enrolled people at stages F1 through F3 and counted improvement as a reduction of at least one stage. Trials report the two separately because they can move independently of one another.
At-risk MASLD
The phase 3 liver trial used a specific entry definition: MASLD with evidence of liver inflammation or fibrosis on non-invasive tests, or biopsy-confirmed MASH. Entry criteria are worth reading, because a trial result describes the group that was actually enrolled rather than everyone with a fatty liver.
How each one is measured
Histology means examining liver tissue taken by biopsy, the most direct evidence available and the hardest to obtain. MRI-PDFF, or magnetic resonance imaging proton density fat fraction, reports what proportion of the liver is fat. MR elastography measures how stiff the liver is, as a stand-in for fibrosis. Iron-corrected T1, written cT1, is a further MRI measure. None of them is a blood test.
Australian context
Where it sits in Australia
Not on the ARTG
A keyword search of the Australian Register of Therapeutic Goods returns no matching results for survodutide. The identical search returns dozens of registered semaglutide products, which confirms the search is working rather than silently failing. Survodutide is not an approved medicine in Australia.
Not approved anywhere
There is no United States Food and Drug Administration approval record and no European Union marketing authorisation. Survodutide is described by its sponsor and in every trial registration as investigational.
Designations are not approvals
Survodutide holds Breakthrough Therapy designation from the FDA for non-cirrhotic MASH and PRIME designation from the European Medicines Agency. Both speed up development and give a sponsor more regulator contact. Neither means a medicine has been assessed and approved, and coverage that treats them as near-approval is wrong.
Not in the Poisons Standard either
Survodutide has no entry in the current Poisons Standard, the June 2026 instrument that sets how tightly each substance is controlled in Australia. That absence is the expected pattern rather than a gap someone has found: the instrument lists medicines in this family individually by name as they are approved, and semaglutide, dulaglutide, liraglutide, exenatide and lixisenatide are all in it. Being absent from a list of controls is not the same as being permitted.
Not named in the TGA peptide warnings
The TGA guidance on unapproved peptide products names BPC-157, GHK-Cu, TB-500, retatrutide and CJC-1295. Survodutide is not among them. That difference reflects what is circulating outside the regulated supply chain, not a finding that one substance is safer than another.
Evidence
What has actually been published
Survodutide is further along than much of what gets discussed alongside it. Its phase 3 results are in peer-reviewed journals, which is worth stating plainly.
Peer reviewed and published
- SYNCHRONIZE-1, phase 3 in obesity without type 2 diabetes, New England Journal of Medicine, 7 June 2026, 725 participants over 76 weeks.
- SYNCHRONIZE-MASLD, phase 3 in fatty liver disease, Nature Medicine, 7 June 2026, 216 participants over 48 weeks.
- Phase 2 trial in MASH with biopsy-confirmed disease, New England Journal of Medicine, July 2024, 293 participants over 48 weeks.
- Phase 2 obesity trial, The Lancet Diabetes and Endocrinology, February 2024, 387 participants over 46 weeks.
Completed or running, without published results
- SYNCHRONIZE-2, in type 2 diabetes, is recorded as completed but only design and baseline papers exist.
- SYNCHRONIZE-CVOT, a cardiovascular outcomes trial of more than five thousand participants, is likewise completed without published outcomes.
- LIVERAGE and LIVERAGE-Cirrhosis, both phase 3 liver trials, were still recruiting at the time of writing.
Reading the evidence
Why two different weight-loss numbers exist
Coverage of the phase 3 obesity trial usually quotes a weight reduction of about 16.6 per cent. The published paper leads with about 13 per cent. Both are real, both come from the same trial, and neither is an error.
Trials report results under an estimand, which is a precise statement of the question being answered. The higher figure answers one question: what would have happened if everyone had stayed on treatment for the whole study? The lower figure answers a different one, and the paper spells it out: the analysis that incorporates early discontinuation, use of obesity medicines the protocol did not permit, and a prolonged escalation period. In plainer terms, what happened across everyone enrolled, whatever they did next.
In this trial that distinction matters more than usual. Roughly 23 to 25 per cent of participants stopped because of adverse effects, against about 5 per cent on placebo. A figure that assumes full adherence is describing a group that, in the trial itself, about a quarter of people did not stay in.
There is a third number that almost never appears at all, and it is the placebo arm. Under the same analysis the published paper leads with, the two survodutide arms came in at 12.2 and 13.0 per cent at week 76 and the placebo arm at 5.4 per cent. Every participant, in all three arms, also received counselling for lifestyle change. So the gap attributable to the medicine under that analysis is closer to seven and a half percentage points than to the figure in the headlines.
Neither number is dishonest, and the higher one is clearly labelled in the source material. But a reader who only ever sees the higher figure is being shown the result of a version of the trial that did not happen.
Liver
The liver evidence
The glucagon receptor acts on the liver, so this is where survodutide has been studied most closely, and where the measurement methods matter most.
Phase 2 used liver biopsy
The phase 2 MASH trial enrolled 293 people with biopsy-confirmed disease and used liver histology as its primary measure. Across the trial arms, 43 to 62 per cent met the endpoint of MASH improvement without worsening fibrosis, against 14 per cent on placebo. Biopsy is the most direct evidence available and the hardest to obtain.
Phase 3 used MRI instead
The phase 3 liver trial measured liver fat by MRI-PDFF rather than biopsy, in 216 people over 48 weeks. Imaging is less invasive, and it answers a narrower question than histology does.
The two-numbers problem is not confined to weight
The liver figure usually quoted is that 84.2 per cent reached at least a 30 per cent reduction in liver fat against 24.3 per cent on placebo. That is the efficacy estimand, the analysis that assumes everyone stayed on treatment. The same paper reports the other analysis in the same sentence: 68.5 per cent against 28.6 per cent. Whichever endpoint you look at on this molecule, check which estimand the number came from before comparing it with anything.
Some of the benefit was not about weight
A later analysis of the phase 2 data found that much of the inflammation and fibrosis benefit was independent of weight reduction, which points to the glucagon receptor acting on the liver directly. The steatosis findings, by contrast, were largely explained by weight change.
No blood test replaced either
ALT, AST and fibrosis indices were measured alongside biopsy and imaging, not instead of them. No published survodutide trial used a blood panel as its liver endpoint.
Testing
What the trials measured
Recorded at fixed protocol timepoints across a study group. Several required imaging or biopsy that no blood panel provides.
Safety
What the side effects were in the trials
The trials are published, which means the safety numbers are public too. That is not true of every molecule discussed alongside this one, and it is worth using.
These are the reported rates, each with its placebo group beside it, because a rate on its own is not a fact about a medicine.
Most people had gastrointestinal effects
In the published phase 3 obesity trial, gastrointestinal symptoms were reported by 80.9 and 89.7 per cent of participants across the two survodutide arms, against 47.9 per cent on placebo. The paper describes them as typically mild to moderate. Note that nearly half the placebo group reported them too, which is a useful reminder of how much a trial needs its control group.
The liver trial gives the sharpest breakdown
The phase 2 MASH trial reported nausea in 66 per cent against 23 per cent on placebo, diarrhoea in 49 against 23, and vomiting in 41 against 4. Serious adverse events were close to level: 8 per cent on survodutide, 7 per cent on placebo. Common and unpleasant is a different category from serious, and the trial reported both.
Timing matters as much as frequency
The phase 3 liver trial records that the most frequently reported adverse events were gastrointestinal, that they commonly occurred while treatment was being stepped up, and that they were generally mild to moderate. An effect concentrated in a stepping-up period is a different prospect from one that persists at a steady state.
This is why the two weight figures differ
Around a quarter of participants stopped because of adverse effects, against about one in twenty on placebo. That is the same fact as the estimand gap explained above. The higher weight-loss figure describes the people who stayed; the lower one counts everyone who enrolled. The side effects and the arithmetic are not two topics, they are one.
No deaths were reported in the phase 3 obesity trial. That is worth stating plainly, and it is also the kind of detail that only exists because these results went through peer review.
Testing
What testing cannot tell you, and what does
Each limit below is followed by what would actually settle the question, which in several cases is something no laboratory can provide.
Questions no blood panel answers here
- Whether liver fat or fibrosis has changed. Biopsy and MRI are what answer it, which is why every published liver endpoint here came from one or the other rather than from a blood panel.
- Whether a particular person would get the published result. Nothing answers that in advance. Trial figures describe averages across a group under a fixed protocol, and the closest available guide is the entry criteria describing who was actually enrolled.
- Whether it is working. Until a regulator approves an indication, nothing answers it, because there is no agreed clinical target for a result to be measured against.
- Whether an unapproved product contains survodutide at all, or contains what its label claims. Only laboratory analysis of the product itself answers that. Testing a person does not test a product.
- Whether use is safe for a particular person. Nothing published answers it, and establishing it is the work of the regulatory assessment no authority anywhere has completed.
What markers do mean, if that is what brought you here
- Blood tests on GLP-1 and GIP medicines in AustraliaThe same questions asked about the medicines in this family that Australia has actually registered, including what their product information says about laboratory tests.
- hs-CRP test AustraliaA marker whose result depends heavily on when the sample was taken, which is the same lesson this page teaches about estimands.
- HOMA-IR AustraliaCalculated from fasting glucose and insulin on the same draw. A short lesson in why one number rarely means anything without another beside it.
- Preventative blood test AustraliaWhat a general preventative panel in Australia contains, and what Medicare does and does not fund for someone without symptoms.
FAQ
Frequently asked questions
- Is survodutide approved in Australia?
- No. A search of the Australian Register of Therapeutic Goods returns no matching results for survodutide, so it is not an approved medicine in Australia. It is not approved in the United States or the European Union either.
- What does the glucagon receptor do?
- Published mechanism work on survodutide describes glucagon receptor activation in the liver as raising energy expenditure, while GLP-1 receptor activity acts in the brain regions that signal fullness and reduces how much a person eats. Those two together are how the molecule is described as lowering body weight, and the liver half is why it has been studied in liver disease.
- What is MASH?
- MASH is metabolic dysfunction-associated steatohepatitis. Steatotic means fatty and hepatitis means inflammation, so MASH is fatty liver disease that has progressed to inflammation and liver cell damage. The broader condition without that inflammation is MASLD. The phase 2 survodutide trial required biopsy-confirmed MASH with fibrosis staged F1 through F3.
- How is survodutide different from GLP-1 and GIP medicines?
- Survodutide is an investigational medicine from Boehringer Ingelheim, co-invented with Zealand Pharma, and the second receptor is what sets it apart. Semaglutide acts on GLP-1 alone and tirzepatide adds GIP, while survodutide adds glucagon. Glucagon receptor activity acts on the liver, which is why survodutide has been studied so heavily in liver disease.
- Did survodutide really produce 16.6 per cent weight loss?
- That figure assumes every participant stayed on treatment for the full study. The published paper leads with roughly 13 per cent, which counts everyone enrolled including those who stopped. Both describe the same trial, and about a quarter of participants discontinued because of adverse effects.
- Has the survodutide phase 3 trial been published?
- Yes. Two phase 3 trials were published on 7 June 2026, one in obesity in the New England Journal of Medicine and one in fatty liver disease in Nature Medicine. The type 2 diabetes and cardiovascular outcome trials have not published results.
- What are the side effects of survodutide?
- Gastrointestinal, mainly. The published phase 3 obesity trial reported them in 80.9 and 89.7 per cent of participants across the survodutide arms against 47.9 per cent on placebo, typically mild to moderate. The phase 2 liver trial reported nausea in 66 per cent against 23 on placebo. Serious adverse events were 8 per cent against 7 on placebo, and no deaths were reported in the obesity trial.
- What did the survodutide liver trial show?
- The phase 2 trial used liver biopsy and found MASH improvement without worsening fibrosis in 43 to 62 per cent across trial arms, against 14 per cent on placebo. The phase 3 liver trial used MRI, and reported 84.2 per cent against 24.3 per cent reaching at least a 30 per cent liver fat reduction on the efficacy estimand, or 68.5 per cent against 28.6 per cent on the other analysis.
- What blood tests monitor survodutide?
- None are established, because no regulator has approved it for any use. The trials measured markers under a study protocol, and their liver endpoints relied on biopsy and MRI rather than blood.
- Does Hemexa prescribe or supply survodutide?
- No. Hemexa does not prescribe, dispense, or supply any medicine or peptide. Hemexa is an Australian preventative blood-testing membership that helps people track their own results over time, and treatment decisions stay with your own doctor.
About this page
Who publishes this page
Hemexa is an Australian preventative blood-testing membership. What we do is turn repeat pathology into trends a person can read over time and take to their own doctor, which is mostly a matter of knowing what a number does and does not mean. This page exists for the same reason: the figure most people have seen for survodutide is not the one in the published paper, and almost nothing explains the difference.
What Hemexa is
- An Australian membership for preventative blood testing and tracking results over time
- A platform that turns repeat pathology into trends a person can discuss with their own doctor
- The publisher of this educational explainer
What Hemexa is not
- Not a prescriber. Hemexa does not prescribe any medicine or peptide.
- Not a pharmacy, and not a supplier of medicines or peptides.
- Not a clinic, and not a route to treatment or access.
How this page is maintained. Last reviewed 15 August 2026.
- Written by
- The Hemexa editorial team. A company publication, so no individual byline.
- Next review triggered by
- Publication of SYNCHRONIZE-2 or SYNCHRONIZE-CVOT, results from the LIVERAGE trials, a regulatory submission or approval in any country, or an ARTG entry appearing.
- Sources
- Every factual claim traces to a numbered primary source below: the Australian regulator, peer-reviewed journals, and trial registrations. Where a regulator has since updated its advice, the regulator page is authoritative.
- Scope
- Regulatory status and evidence quality. This page does not recommend, supply, or help anyone obtain anything, and it gives no amounts or protocols.
Nothing here is medical advice. Read the health disclaimer, and take any question about your own treatment to your doctor.
Sources
References
Primary sources, with the date each was accessed. Where a regulator has updated its advice, the regulator page is authoritative over this summary.
Therapeutic Goods Administration. Australian Register of Therapeutic Goods search. Searched for survodutide, no matching results, 15 August 2026. Accessed 15 August 2026.
ClinicalTrials.gov. SYNCHRONIZE-1 trial registration, NCT06066515. Phase 3, sponsor Boehringer Ingelheim, registered 2023. Accessed 15 August 2026.
New England Journal of Medicine. SYNCHRONIZE-1 phase 3 trial of survodutide in obesity. Published 7 June 2026. Accessed 15 August 2026.
Nature Medicine. SYNCHRONIZE-MASLD phase 3 trial of survodutide in fatty liver disease. Published 7 June 2026. Accessed 15 August 2026.
New England Journal of Medicine. Phase 2 trial of survodutide in biopsy-confirmed MASH. Published July 2024. Accessed 15 August 2026.